Anti-Mouse Properdin TSR 5/6 Monoclonal Antibodies Block Complement Alternative Pathway-dependent Pathogenesis
Anti-Mouse Properdin TSR 5/6 Monoclonal Antibodies Block Complement Alternative Pathway-dependent Pathogenesis
复制标题
DOI：
10.1089/mab.2014.0066
复制
发表时间：
2015-02-01
影响因子：
--
通讯作者：
Hourcade, Dennis E.
中科院分区：
文献类型：
--
作者：
Bertram, Paula;Akk, Antonina M.;Hourcade, Dennis E.
补体替代途径（AP）是广泛和日益增长的疾病的主要贡献者，包括年龄相关性黄斑变性，非典型溶血性尿毒症综合征和先兆子痫。因此，对AP活性的治疗性破坏非常感兴趣。作为唯一对AP有利的监管者，Properdin是一个特别有希望的AP目标。在实现靶向治疗的潜力之前，需要澄清几个问题。在本报告中，我们使用在细菌系统中表达的一部分小鼠properdin蛋白来培养兔多克隆和仓鼠单克隆抗体，以阻断properdin依赖性发病机制。当这些抗体用于ap依赖性小鼠疾病模型时，可以帮助评估propertin定向治疗的可行性。
The complement alternative pathway (AP) is a major contributor to a broad and growing spectrum of diseases that includes age-related macular degeneration, atypical hemolytic uremic syndrome, and preeclampsia. As a result, there is much interest in the therapeutic disruption of AP activity. Properdin, the only positive regulator of the AP, is a particularly promising AP target. Several issues need to be clarified before the potential for properdin-directed therapy can be realized. In this report we use a portion of the mouse properdin protein, expressed in a bacterial system, to raise rabbit polyclonal and hamster monoclonal antibodies that block properdin-dependent pathogenesis. These antibodies, when employed with AP-dependent mouse disease models, can help evaluate the feasibility of properdin-directed therapy.